| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3333511 | Seminars in Hematology | 2015 | 12 Pages |
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma. Next-generation sequencing techniques have improved our understanding of the molecular pathways that may drive oncogenesis. Many novel classes of drugs are in development that may improve the treatment of DLBCL, either as single agents or in combination, that exploit their synergy to overcome resistance. We review the key novel targets and therapeutics in the treatment of DLBCL, including immunomodulatory agents and immunotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Neha Mehta-Shah, Anas Younes,